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Abstract More than 30 years ago, Judah Folkman found a
revolutionary new way to think about cancer. He postulated
that in order to survive and grow, tumors require blood ves-
sels, and that by cutting off that blood supply, a cancer could
be starved into remission. What began as a revolutionary
approach to cancer has evolved into one of the most exciting
areas ofscientiﬁcinquirytoday.Overthe years,Folkmanand
a growing team of researchers have isolated the proteins and
unraveled the processes that regulate angiogenesis. Mean-
while, a new generation of angiogenesis research has
emerged as well, widening the ﬁeld into new areas of human
diseaseanddeepeningittoexaminetheunderlyingbiological
processes responsible for those diseases.
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Early evidence of tumor cells releasing speciﬁc growth
factor for blood vessels
In 1939, Ide et al. [1] were the ﬁrst to suggest that tumors
release speciﬁc factors capable of stimulating the growth of
blood vessels. In 1945, Algire and Chalkley [2] were the
ﬁrst to appreciate that growing malignancies could con-
tinuously elicit new capillary growth from the host. They
used a transparent chamber implanted in a cat’s skin to
study the vasoproliferative reaction secondary to a wound
or implantation of normal or neoplastic tissues. They
showed that the vasoproliferative response induced by
tumor tissues was more substantial and earlier than that
induced by normal tissues or following a wound. They
concluded that the growth of a tumor is closely connected
to the development of an intrinsic vascular network.
In 1956, Melwin and Algire [3] found that the vaso-
proliferative response of normal or neoplastic tissues
transplanted into muscle was not signiﬁcantly different
with respect to the time of onset of new blood vessels,
though it was stronger when the implantation was per-
formed in a resection area. In addition, while normal
tissues induced a vasoproliferative response conﬁned to the
host, tumor tissues induced the formation of neovessels that
pierced the implant. Lastly, the intensity of the response
seemed to be inﬂuenced by the distance between the
implant and the host’s vessels: normal tissue was unable to
induce a response if placed more than 50 lm away,
whereas tumor tissue had a longer activity range.
In 1968, Greenblatt and Shubik [4] implanted Millipore
chambers (pore size 0.45 lm) into a hamster’s cheek pouch
and placed some tumor fragments around them. In a few
days, the growing tumor mass engulfed the whole chamber,
whose pores were permeable to the tumor interstitial ﬂuid,
but not to the tumor cells. New blood vessels, however,
were formed in any case very likely through the release of a
diffusible factor that could pass through the pores. Ehrman
and Knoth [5] conﬁrmed these data with tumor fragments
laid on Millipore ﬁlters planted on the chick embryo cho-
rioallantoic membrane (CAM).
Tumors in isolated perfused organs: absence
of angiogenesis
In 1963, Folkman and Becker studied hemoglobin solu-
tions as potential substitutes for blood transfusion. To test
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fused these solutions through the vasculature of canine
thyroid glands, by using an apparatus with a silicone rubber
oxygenator. The glands survived for about 2 weeks. They
could distinguish different hemoglobin preparations by
histologic analysis of the thyroid glands after a week or
more of continuous arterial perfusion. To determine if these
isolated organs could support growth, they injected them
with adult mouse melanoma cells. Tiny tumors developed
but stopped growing at 1- to 2-mm diameter and never
became vascularized [6]. Endothelial cells swelled and
could not proliferate in the presence of free hemoglobin
solutions lacking platelets [7]. However, the tumors were
not dead. When they were transplanted to their host mice,
they rapidly vascularized and grew to more than 1 cm
3.
Folkman et al. observed that when tumor cells were
inoculated into isolated perfused organs, tumors were
limited in size to 1–2 mm
3 [6]. Subsequently, they found
that neovascularization does not occur in isolated perfused
organs and that tumors transplanted from these organs to
syngeneic mice became vascularized and grew rapidly to
1–2 mm
3. This was the ﬁrst evidence that the absence of
neovascularization correlated with severe restriction of
tumor growth.
The data were consistent with work from Harry Green,
who had shown long before that growth of rabbit tumors
transplanted into the anterior chamber of the guinea pig
coincided with the growth of new blood vessels. Tumors
that remained viable, but did not grow, had no visible blood
vessels [8].
Hypothesis: tumor growth is angiogenesis dependent
In 1971, Folkman published in the ‘‘New England Journal
of Medicine’’ a hypothesis that tumor growth is angio-
genesis dependent and that inhibition of angiogenesis could
be therapeutic [9]. This article also introduced the term
anti-angiogenesis to mean the prevention of new vessel
sprout from being recruited by a tumor. The hypothesis
predicted that tumors would be enable to grow beyond a
microscopic size of 1–2 mm
3 without continuous recruit-
ment of new capillary blood vessels.
This concept is now widely accepted because of sup-
porting data from experimental studies and clinical
observations carried out over the intervening years.
Evidence that tumors are angiogenesis dependent
Folkman and collaborators provide evidence for the
dependence of tumor growth on neovascularization:
(1) Tumor growth in the avascular cornea proceeds
slowly at a linear rate, but after vascularization,
tumor growth is exponential [10].
(2) Tumors suspended in the aqueous ﬂuid of the anterior
chamber of the rabbit eye and observed for a period
up to 6 weeks remain viable, avascular, and of limited
size (less than 1 mm
3) and contain a population of
viable and mitotically active tumor cells. These
tumors induce neovascularization of the iris vessels
but are too remote from these vessels to be invaded by
them. After implantation contiguous to the iris, which
had abundant blood vessels, the tumors induced
neovascularization and grow rapidly, reaching
16,000 times the original size within 2 weeks [11].
This experiment introduced the concept of tumor
dormancy brought about by prevention of neovascu-
larization. In a parallel study, tumors were suspended
in the aqueous humor of the anterior chamber, placed
at various distances from the iris vessels, and
compared with tumors implanted directly on the iris
and with those implanted in the cornea [12]. Moving
the distant, dormant tumors closer to the iris jump
started their growth. This suggested that this type of
tumor dormancy was caused not by cell cycle arrest
or immune control, but by a lack of blood supply.
(3) B-16 mouse melanoma, V-79 Chinese hamster lung
cells, and L-5178 Y murine leukemia cells were
plated in soft agar [13]. After 6–7 days of incubation,
spheroid colonies of 0.1 mm were visible. All spher-
oids ﬁrst enlarged exponentially for a few days and
then continued on a linear growth curve for 5–
23 weeks before reaching a diameter beyond which
there was no further expansion. This was termed the
dormant phase. After the dormant diameter was
reached, these spheroids remained viable for 3–
5 months, or as long as they were frequently trans-
ferred to new medium. Cells in the periphery of the
spheroid incorporated
3H-labeled thymidine while
cells in the center died. This is a form of population
dormancy in which the proliferating cells near the
surface of the spheroid just balance those dying cells
deep in the center of the spheroid.
(4) Tumors implanted on the CAM of the chick embryo
do not exceed a mean diameter of 0.93 ± 0.29 mm
during the prevascular phase (approximately 72 h).
Rapid growth begins, however, within 24 h after
vascularization, and tumors reach a mean diameter of
8.0 ± 2.5 mm by 7 days [14].
(5) Tumors grown in the vitreous of the rabbit eye remain
viable but attain diameters of less than 0.50 mm for
as long as 100 days. Once such a tumor reaches the
retinal surface, it becomes neovascularized and within
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1232 weeks can undergo a 19,000-fold increase in
volume over the avascular tumor [15].
(6) The CAM appears at day 5 during development of the
chick embryo. The
3H-thymidine labeling index of its
vascular endothelium decreases with age, with an
abrupt reduction at day 11 [16]. Prior to day 11,
labeling index is approximately 23%; during 11 days,
the labeling index decreases to 2.8%, and subse-
quently, the cells begin to acquire the structural
characteristics of matured, differentiated endothe-
lium. One-millimeter fragments of fresh Walker 256
carcinoma were implanted on the CAM from day 3 to
day 16 [14]. The size of the tumors was measured
daily, and the onset of vascularization of each tumor
was determined in vivo with a stereomicroscope and
conﬁrmed with histological sections. Proliferation of
chick capillaries occurred in the neighborhood of the
tumor graft by 24 h after implantation, but capillary
sprouts did not penetrate the tumor graft until
approximately 72 h. During the avascular phase,
tumor diameter did not exceed 1 mm. Small tumor
implants of 0.5 mm or less grew to 1 mm and stopped
expanding. Larger tumor implants of 2- or 3-mm
shrank until they reached 1-mm diameter. During the
ﬁrst 24 h after penetration by capillaries, there was a
rapid tumor growth. Neovascularization was not
grossly observable with the stereomicroscope until
after day 10 or 11. Tumors implanted on the CAM
after day 11 grow at slower rate in parallel with the
reduced rates of endothelial growth.
(7) When tumor grafts of increasing size (from 1 to
4 mm) are implanted on the 9-day CAM, grafts larger
than 1 mm undergo necrosis and autolysis during the
72-h prevascular phase. They shrink rapidly until the
onset of neovascularization, when rapid tumor growth
resumes [14]. In another study [17], the behavior of
tumor grafts on the CAM was compared to grafts of
normal adult and embryonic tissues. In tumor tissue,
preexisting blood vessels within the tumor graft
disintegrated by 24 h after implantation. Neovascu-
larization did not occur until after at least 3 days, and
only by penetration of proliferating host vessels into
the tumor tissue. There was marked neovasculariza-
tion of host vessels in the neighborhood of the tumor
graft. By contrast, in embryonic graft, preexisting
vessels did not disintegrated. They reattached by
anastomosis to the host vessels within 1–2 days, but
with minimal or almost no neovascularization on the
part of the host vessels. In adult tissues, the preex-
isting graft vessels disintegrated; there was no
reattachment of their circulation with the host, and
adult tissues did not stimulate capillary proliferation.
These studies suggest that only tumor grafts are
capable of stimulating formation of new blood vessels
in the host.
(8) In transgenic mice that develop carcinomas of the b
cells in the pancreatic islets, large tumors arise only
from a subset of preneoplastic hyperplastic islets that
have become vascularized [18].
Isolation of the ﬁrst angiogenic tumor factor
Until the early 1970s, it was widely assumed that tumors
did not produce speciﬁc angiogenic proteins. The con-
ventional widsom was that tumor vasculature was an
inﬂammatory reaction to dying or necrotic tumor cells.
Previous studies had shown that tumor-stimulated vessel
growth did not require direct contact between tumor and
host tissue [4, 5]. This made sense to Folkman, who rea-
soned that a soluble factor would be more likely to reach
nearly than distant blood vessels. He and his colleagues
isolated an angiogenic factor in 1971 [19]. The homogenate
of a Walker 256 carcinoma—a breast tumor of Sprague-
Dawley rats—was fractionated by gel-ﬁltration on Sepha-
dex G-100. The fraction that exhibited the strongest
angiogenic activity had a molecular weight of about
10,000 daltons and consisted of 25% RNA, 10% proteins,
and 58% carbohydrates, plus a possible lipid residue. It was
inactivated by digestion with pancreatic ribonuclease, or by
heating at 56C for 1 h, and was not modiﬁed when kept at
4C for 3 months, nor when treated with trypsin for more
than 3 days. This active fraction was subsequently called
‘‘tumor angiogenesis factor’’ (TAF) [19]. Both the cyto-
plasmic and the nuclear fractions of tumor cells stimulated
angiogenesis. In the nuclear fraction, this was found to be
associated with nonhistonic proteins [20]. Tumor angio-
genesis factor has since been nondestructively extracted
from several tumor cell lines, and several low molecular
weight angiogenic factors have been isolated, again from
the Walker 256 carcinoma. These factors induced a vaso-
proliferative response in vivo when tested on rabbit cornea
or chick CAM, and in vitro on cultured endothelial cells
[21–23].
First evidence of the existence of the avascular
and vascular phases of solid tumor growth
The earliest evidence of the existence of the two phases
was obtained by Folkman and collaborators in 1963, who
perfused the lobe of a thyroid gland with plasma and
inoculated a suspension of melanoma B16 tumor cells
through the perfusion ﬂuid. These cells grew into small,
clearly visible black nodules. The nodules did not exceed
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1231 mm in diameter and did not connect with the host’s
vascular network. Their outer third generally remained
vital, while the interior portion underwent necrosis.
Reimplanted nodules, on the other hand, equipped them-
selves with a vascular network and grew very rapidly. The
conclusion was thus drawn that the absence of vasculari-
zation limits the growth of solid tumors.
Further research by Folkman’s group resulted in an
experimental system in which the tumor, or its extracts,
could be separated from the vascular bed [24, 25]. This
system was based on subcutaneous insufﬂation to lift the
skin of a rat and form a poorly vascularized region below
it. Millipore ﬁlters containing Walker 256 cancer cells or
their cytoplasmic or nuclear extracts (TAF) were implanted
into the fascial ﬂoor of the dorsal air sac. At intervals
thereafter,
3H-labeled thymidine was injected into the air
sac, and the tissues were examined by autoradiography and
electron microscopy. Autoradiographs showed thymi-
dine-
3H labeling in endothelial cells of small vessels, 1–
3 mm from the site of implantation, as early as 6–8 h after
exposure to tumor cells. DNA synthesis by endothelium
subsequently increased, and within 48 h new blood vessels
formation was detected. The presence of labeled endothe-
lial nuclei, endothelial mitosis, and regenerating
endothelium was conﬁrmed by electron microscopy.
Tumor angiogenesis factor also induced neovascularization
and endothelial DNA synthesis after 48 h. Further ultra-
structural autoradiographic studies were carried out with
the same model [25]. It was apparent that by 48 h there was
ultrastructural evidence of regenerating endothelium,
including marked increase in ribosomes and endoplasmic
reticulum, scarce or absent pinocytotic vesicles, and dis-
continuous basement membrane. Labeled endothelial cells
were seen along newly formed sprouts as well as in parent
vessels. Furthermore, pericytes were also shown to syn-
thesize DNA.
In another series of experiments, 1-mm fragments from
Brown-Pearce and V2 carcinomas were implanted into the
avascular stroma of a rabbit cornea 1–6 mm away from the
limbic vessels, and observed the tumor growth daily with a
stereomicroscope [10]. After 1 week, new blood vessels
had invaded the cornea starting from the edge closer to the
site of implantation and developed in that direction at
0.2 mm and then about 1 mm/day. Once the vessels
reached the tumor, it grew very rapidly to permeate the
entire globe within 4 weeks.
Dormancy of micrometastases may be governed
by angiogenesis
Folkman and collaborators found that metastases were
suppressed when a primary tumor was implanted and
allowed to grow in nude mice, whereas they underwent
neovascularization and became clinically evident when
primary neoplasm was removed. In the absence of angio-
genesis, micrometastases rarely exceeded 0.2-mm diameter
and contained many proliferating tumor cells balanced by
many apoptotic cells. When they were allowed to become
angiogenic, they grew rapidly. Dormancy may be gener-
alizable to a variety of tumors in which blocked
angiogenesis results in balanced tumor cell proliferation
and apoptosis [26].
Prognostic signiﬁcance of tumor vascularity
In 1972, Brem in the Folkman laboratory reported the ﬁrst
quantitative method for histologic grading of tumor angi-
ogenesis. He correlated neovascularization in human brain
tumors with tumor grade [27]. In the early 1990s, Weidner
and collaborators [28–30] showed that measurement of
microvascular density within isolated regions of high ves-
sel concentration (i.e., hotspots) was a prognostic indicator
for human breast and prostate carcinomas.
Microvascular density counting protocols have become
the morphological gold standard to assess the neovascula-
ture in human tumors. This method requires the use of
speciﬁc markers to vascular endothelium and of immuno-
histochemical procedures to visualize microvessels.
Microvascular density determined in primary tumors is
signiﬁcantly associated with metastasis and prognosis in
several solid and hematological tumors.
Antiangiogenesis
The existence of speciﬁc angiogenesis inhibitors was ﬁrst
postulated by Folkman in 1971 in an editorial. No angio-
genesis inhibitors existed before 1980, and few scientists
thought at that time that such molecules would ever be
found.
From 1980 to 2005, Folkman’s laboratory reported the
discovery of 12 angiogenesis inhibitors (Table 1). The
ﬁrst angiogenesis inhibitor was found in cartilage, an
avascular tissue that resists invasion by many tumors [31].
Brem and Folkman demonstrated that tumor-induced
vessels were inhibited by a diffusible factor from neonatal
rabbit cartilage [32]. The partially puriﬁed inhibitor
suppressed tumor growth when it was infused into the
vascular bed of murine and rabbit tumors [33]. 2-meth-
oxyestradiol was ﬁrst reported by Fotsis et al. [34], and
the article reporting 2-methoxyoestradiol and its molecu-
lar mechanism as an inhibitor of tubulin polymerization
by acting at the colchicine site was published a month
later [35].
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Interferon alpha was ﬁrst shown to inhibit endothelial cell
migrationinadose-dependentandreversiblemannerin1980
by Zetter in Folkman’s laboratory [36]. Since 1988, inter-
feronalphahasbeenusedsuccessfullytocausecompleteand
durable regression of life-threatening pulmonary hemangi-
omatosis, hemangiomatosis of the brain, airway and liver in
infants, recurrent high-grade giant cell tumors refractory to
conventional therapy, and angioblastomas [37–39].
A 12-year-old boy with fatal pulmonary hemangioma-
tosis had a complete remission and recovered completely
after 7 months of therapy with interferon alpha. Therapy
was continued for 7 years. This led to the successful use of
low-dose daily interferon alpha therapy administered sub-
cutaneously to infants with sight-threatening or life-
threatening hemangiomas and hemangioendotheliomas of
the heart, airway, and liver [37–39].
Platelet factor 4/protamine
Protamine was shown to be an angiogenesis inhibitor [40],
but cumulative toxicity from prolonged administration and
a narrow window of angiostatic efﬁcacy prevented its
consideration for clinical use.
Platelet factor 4 was ﬁrst tested for antiangiogenic
activity because its method of binding and neutralizing
heparin is similar to that of protamine [40]. Recombinant
human platelet factor 4 (rHuPF4) has been produced [41].
It speciﬁcally inhibited endothelial proliferation and
migration in vitro [42]. The inhibitory activities are
associated with the carboxy-terminal region of the mole-
cule. The growth of human colon carcinoma in athymic
mice, as well as the growth of murine melanoma, was
markedly inhibited by intralesional injections, whereas
tumor cells were completely insensitive to rHuPF4 in
vitro at levels that inhibited normal endothelial cell pro-
liferation. Systemic administration of rHuPF4 has so far
been ineffective against tumor growth, perhaps because of
rapid inactivation or clearance of the peptide.
Angiostatic steroids
Folkman had begun to use the CAM of the chick embryo to
detect angiogenic activity in fractions being puriﬁed from
tumor extracts. The addition of heparin increased the speed
of development of the angiogenic reaction so that it could
be read 1–2 days later [40]. But one problem with this
assay is that occasionally eggshell dust falls on the CAM
and causes background inﬂammation. Folkman guessed
that adding cortisone to the CAM might eliminate the
irritation from the shell dust but not abolish the tumor-
angiogenic reaction. As expected, cortisone alone pre-
vented shell dust inﬂammation without interfering with
angiogenesis induced by tumor extracts. The surprise was
that when heparin and cortisone were added together,
tumor angiogenesis was inhibited [43]. Furthermore, when
this combination of heparin and steroid was suspended in a
methylcellulose disk and implanted on the young (6-day)
CAM, growing capillaries regressed leaving in their place,
48 h later, an avascular zone. The antiangiogenic effect
was speciﬁc for growing capillaries. Mature nongrowing
capillaries in older membranes were unaffected. Nonanti-
coagulant heparin had the same effect. A hexasaccharide
fragment with a molecular weight of approximately 16,000
was found to be the most potent inhibitor of angiogenesis
(in the presence of a corticosteroid). The combination of
the heparin hexasaccharide fragment and cortisone also
inhibited tumor-induced angiogenesis in the rabbit cornea.
The regression of a growing vessel exposed to heparin-
steroid combinations begins with endothelial cell rounding
and is followed by cessation of endothelial proliferation,
desquamation of endothelial cells, and retraction of the
capillary sprout [44]. These events occur as 24–48 h and
are accompanied by dissolution of the basement membrane
of the new capillary vessels.
Fumagillin
Fumagillin was found by Ingber in the Folkman laboratory
to inhibit endothelial cell proliferation without causing
endothelial cell apoptosis, when a tissue culture plate of
endothelial cells became contaminated with a fungus
Aspergillus fumigatus fresenius [45]. A conditioned med-
ium from fungal cultures contained an inhibitor of
endothelial cell proliferation and angiogenesis, which, upon
puriﬁcation, was found to be fumagillin, a polyene macro-
lide. When capillary endothelial cells were stimulated by
ﬁbroblast growth factor-2 (FGF-2), half-maximal inhibition
Table 1 Angiogenesis
inhibitors discovered in
Folkman’s laboratory from
1980 to 2005
1980. Interferon alpha-beta
1982. Platelet factor 4/
protamine
1985. Angiostatic steroids
1990. Fumagillin
1994. Angiostatin
1994. Thalidomide
1994. 2-methoxyestradiol
1997. Endostatin
1999. Cleaved antithrombin III
2002. 3-Aminotholidomide
2003. DBF-maf
2005. Caplostatin
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liferative effect appeared to be relatively speciﬁc for
endothelial cells because inhibition of nonendothelial cells,
including tumor cells, was observed at up to 1,000-fold
higher concentrations.
Scientists at Takeda Chemical Industries (Osaka, Japan)
made a synthetic analogue of fumagillin, called TNP-470,
which inhibits endothelial proliferation in vitro at a con-
centration 3 logs lower than the concentration necessary to
inhibit ﬁbroblasts, and tumor cells.
Angiostatin and endostatin
They were discovered by M. O’Reilly in Folkman labora-
tory based on Folkman’s hypothesis of a mechanism to
explain the phenomenon that surgical removal of certain
tumors leads to rapid growth of remote metastases. This
hypothesis said that if tumors produce both stimulators and
inhibitors of angiogenesis, an excess of inhibitors could
accumulate within an angiogenic tumor. In the circulation
however, the ratio would be reversed. Angiogenesis
inhibitors would increase relative to stimulators, because of
rapid clearance of stimulators from the blood. Folkman
formulated this hypothesis after reading Bouck’s ﬁrst
report in 1989 that the emergence of tumor angiogenesis
was the result of a shift in balance between positive and
negative regulators of angiogenesis in a tumor [46]. Bouck
reported that the switch to angiogenesis during tumori-
genesis of transformed hamster cells was associated with
downregulation of an inhibitor of angiogenesis, thrombo-
spondin. She suggested that the switch to the angiogenic
phenotype could be the result of a shift in the net balance of
positive and negative regulators of angiogenesis.
In 1991, O’Reilly began to screen a variety of trans-
plantable murine tumors for their ability to suppress
metastases. A Lewis lung carcinoma was the most efﬁcient.
When the metastasis-suppressing primary tumor was
present in the dorsal subcutaneous position, microscopic
lung metastases remained dormant at a diameter of less
than 200 lm surrounding a preexisting microvessel, but
revealed no new vessels. Within 5 days after surgical
removal of the primary tumor, lung metastases became
highly angiogenic and grew rapidly, killing their host by
15 days [47]. This striking evidence that primary tumor
could suppress angiogenesis in its secondary metastases by
a circulating inhibitor was further supported by the dem-
onstration that a primary tumor could also suppress corneal
angiogenesis by an implanted pellet of FGF-2. O’Reilly
then succeeded in purifying this inhibitor from the serum
and urine of tumor-bearing animals. It was a 38-kD internal
fragment identical in amino acid sequence to the ﬁrst four
kringle structures of plasminogen and it was named
angiostatin. Angiostatin speciﬁcally inhibited the prolifer-
ation of growing vascular endothelial cells and had no
effect on resting conﬂuent endothelial cells or on other cell
types, including smooth muscle cells, epithelial cells,
ﬁbroblasts and tumor cells. It also inhibited growth of
primary tumors by up to 98% [48] and was able to induce
regression of large tumors (1–2% of body weight) and
maintain them at a microscopic dormant size.
Based on the same rationale and strategy, O’Reilly
isolated and puriﬁed another angiogenesis inhibitor from a
murine hemangioendothelioma. This inhibitor, called
endostatin [49], is a 20-kD protein with an N-terminal
amino acid sequence identical to the carboxyterminus of
collagen XVIII. It was puriﬁed directly from tumor cell-
conditioned medium. Endostatin is also a speciﬁc inhibitor
of endothelial proliferation and has no effects on resting
endothelial cells or on other cell types. It is slightly more
potent than angiostatin and also causes regression of large
tumors to a microscopic size.
Thalidomide
In 1994, D’Amato in the Folkman laboratory reported that
thalidomide is an angiogenic inhibitor [50]. Corneal neo-
vascularization in rabbits induced by FGF-2 or VEGF was
blocked by orally administered thalidomide. This activity of
thalidomide was mainly the result of its direct effect on
inhibitingnewbloodvesselformationandnotonsuppression
of inﬁltrating host inﬂammatory cells. Histologic sections of
the pretreated neovascularized corneas were virtually free of
inﬂammatory cells. Thalidomide also inhibited corneal neo-
vascularization in mice, but it was necessary to give the drug
by the intraperitoneal route and at high doses, because mice
do not metabolize thalidomide effectively.
2-Methoxyestradiol
In 1994, D’Amato in Folkman laboratory demonstrated
that a metabolite of estradiol, 2-methoxyestradiol, inhibited
angiogenesis in the chick CAM [35]. Moreover, since 2-
methoxyestradiol causes mitotic perturbations, they
examined its interactions with tubulin and showed that 2-
methoxyestradiol bound to colchicine site of tubulin and,
depending on reaction conditions, either inhibited assembly
or seems to be incorporated into a polymer with altered
stability properties.
Cleaved antithrombin III
A human small-cell lung carcinoma suppressed angiogen-
esis and tumor growth at remote sites in immunodeﬁcient
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verted the 58-kD conformation of circulating antithrombin
III to a 53-kD form of the protein [51] in which the
externally conﬁgured stressed loop of antithrombin was
retracted into the body of the molecule. The 53-kD form is
a speciﬁc endothelial inhibitor and a potent angiogenesis
inhibitor and has no thrombin binding activity.
Caplostatin
Caplostatin is a nontoxic synthetic analogue of fumagillin
conjugated to a water-soluble-N-(2-hydroxypropyl)meth-
acrylamide (HPMA) copolymer [52, 53]. Caplostatin has a
similar broad antitumor spectrum of TNP-470 without any
toxicity. In addition to its antiangiogenic activity, cap-
lostatin is the most potent known inhibitor of vascular
permeability [53]. Caplostatin prevents vascular leakage
induced by VEGF, bradykinin, histamine, and platelet-
activating factor and prevents pulmonary edema induced
by interleukin-2.
Antiangiogenic chemotherapy
Browder in the Folkman laboratory was the ﬁrst to dem-
onstrate the concept that by optimizing the dosing schedule
of conventional cytotoxic chemotherapy to achieve more
sustained apoptosis of endothelial cells in the vascular bed
of a tumor, it is possible to achieve more effective control
of tumor growth in mice, even if the tumor cells are drug
resistant [54]. Conventional chemotherapy is administered
at maximum tolerated doses followed by off-therapy
intervals of 2–3 weeks to allow the bone marrow and
gastrointestinal tract to recover. In contrast, antiangiogenic
chemotherapy is administered more frequently at lower
doses, without long interruptions in therapy and with little
or no toxicity. During antiangiogenic chemotherapy,
endothelial cell apoptosis and capillary dropout precede the
death of tumor cells that surround each capillary.
Concluding remarks
Currently, several compounds with angiostatic activity are
approved for clinical use, and many are in late-stage clin-
ical development. However, the results from clinical trials
have not shown the antitumor effects which were expected
following preclinical studies. It appears that clinical
applications of antiangiogenic therapy are more complex
than originally thought.
The main problem in the development of antiangiogenic
agents is that multiple angiogenic molecules may be
produced by tumors, and tumors at different stages of
developmentmaydependondifferentangiogenicfactorsfor
their blood supply. Therefore, blocking a single angiogenic
molecule was expected to have little or no impact on tumor
growth. Current development of targeted antiangiogenic
agents include their use in adjuvant settings and the combi-
nation of different antiangiogenic inhibitors to take a more
comprehensive approach in blocking tumor angiogenesis.
Advancing insights into fundamental mechanisms will
be necessary in the development of novel anticancer
strategies based on inhibition of angiogenesis.
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